Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
2020/3093 NIRADO
The George Institute
DNA repair-deficient or platinum-sensitive solid tumors
1 trial -
202000570
Disc Medicine
Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).
1 trial -
20200491
Amgen
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
2021-SR-545
The First People's Hospital of Lianyungang
Lymphoma, Large B-Cell, Diffuse
1 trial -
2021/3330 HOLMBRAVE
The George Institute
Non resectable Hepatocellular carcinoma (HCC)
1 trial -
20210023
Amgen
Advanced MTAP-null solid tumors
1 trial -
20220127
Amgen
In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer
1 trial -
2023-1-69-001
Ningbo Cancer Hospital
Hepatocellular carcinoma
1 trial -
2023-SR-002
The First People's Hospital of Lianyungang
NK-T-Cell Lymphoma, Extranodal
1 trial -
2023/3610 NEOSARC
The George Institute
Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma
1 trial -
2023/3668
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
2024-HS-022
The First People's Hospital of Lianyungang
Platinum-sensitive Relapsed Ovarian Cancer
1 trial -
2024/3967
The George Institute
Advanced non-small cell lung cancer
1 trial -
20240092
Amgen
Small Cell Lung Cancer (SCLC)
1 trial -
2025-SR-813
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
2026（225）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cancer of Biliary Duct
1 trial -
20289
Bayer AG
Solid tumors harboring NTRK fusion
1 trial -
20290
Bayer AG
Solid tumors harboring NTRK fusion
1 trial -
213357
TESARO Bio Netherlands B.V.
Ovarian Neoplasms
1 trial -
213403
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
213824
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
219590
GlaxoSmithKline
Neoplasms
1 trial -
2215-CL-0603
Astellas Pharma GmbH
FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
1 trial -
222730
GlaxoSmithKline
Ovarian Neoplasms
1 trial -
222892
GlaxoSmithKline
MMRp/ MSS colon cancer
1 trial -
223050
GlaxoSmithKline
Neoplasms, Prostate
1 trial -
223675
GlaxoSmithKline
Gastrointestinal Neoplasms
1 trial -
224035
GlaxoSmithKline
Neoplasms, Colorectal
1 trial -
225Ac-J591
United Therapeutics Europe Ltd
Prostate Cancer
2 trials -
225Ac-LNC1011
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
22752
Bayer AG
HER2 mutation, Advanced solid tumors
1 trial -
2X-121
Allarity Therapeutics
Advanced Ovarian Cancer
1 trial -
300148
GlaxoSmithKline
Neoplasms
1 trial -
3124001
Orion Laboratories Pty.
Metastatic castration-resistant prostate cancer.
1 trial -
3134003
Orion Laboratories Pty.
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
1 trial -
42756493BLC2001
Janssen-Cilag International N.V.
Urothelial cancer
1 trial -
42756493BLC2002
Janssen-Cilag International N.V.
Metastatic or Locally Advanced Urothelial Cancer
1 trial -
42756493BLC2003
Janssen-Cilag International N.V.
Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions
1 trial -
42756493CAN2002
Janssen-Cilag International N.V.
Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.
1 trial -
5-Fluorouracil
Hospital Authority, Hong Kong
Cancer (Advanced Stage)
1 trial -
5-Fluorouracil (5-FU)
HALOZYME THERAPEUTICS, INC.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
1 trial -
54179060CLL2032
Janssen-Cilag International N.V.
Untreated Chronic Lymphocytic Leukemia
1 trial -
54179060MCL3004
Janssen-Cilag International N.V.
Relapsed/Refractory Mantle Cell Lymphoma
1 trial -
54767414LEU2002
Wuhan Createrna Science and Technology Co., Ltd
Primary plasma cell leukemia
1 trial -
5541-CL-0201
Astellas Pharma GmbH
Prostate Cancer
1 trial -
609A
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Sarcoma, Soft Tissue
1 trial -
61186372GIC2002
Janssen-Cilag International N.V.
Advanced or Metastatic Colorectal Cancer
1 trial -
61186372HNC2002
Janssen-Cilag International N.V.
Head and Neck Squamous Cell Carcinoma
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.